JPH06704B2 - Treatment of diseases with herpes virus - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to the treatment of herpesvirus diseases, vitiligo, acne and contact dermatitis.

Herpes virus, especially herpes simpl
ex virus) is one of the most common and dangerous problems facing complaints. It is estimated that 75% of the population is affected by the herpes simplex virus.

It is asymptomatic in most cases but quite commonly develops chronically in the mouth, face and genital areas. Pubic herpes is the second most common illness, caused by sexual intercourse, with 100,000 attacks each year in the United States. Orofacial symptoms, often referred to as "fever blisters" or "cold sores", occur quite commonly. Initially it occurs as a stimulus site, but becomes a blister within a few hours. These vesicles generally rupture and cause a secondary infection, and the peripheral part of the skin spreads to the mucous membrane and leaves an ulcer site, which is healed by a normal immune reaction within about 10 to 14 days.

After the initial infection, the patient produces a group of antibodies that eventually drive herpesviruses to a latent state. The virus is reactivated by various factors such as ultraviolet rays, fever, stress, fatigue and trauma. Despite local indiscriminate rash despite the presence of antibody groups, generally 10 to 10
It will follow the healing process for a day.

Abundant “folk remedies” based on the general character of the disease
In addition, the medical literature is full with information on the etiology, analysis and treatment of herpesviruses. For a good overview of herpesviruses and a good summary of treatments, see Dr. Littell ["Drug Therapy," p. 27, by Mlchael W.
Rytel, MD, entitled "Herpes Slmplex lnfections" Sept
ember, 1976].

The only drug that has been found to be effective in the treatment of herpes simplex is idoxuridine eye drops for herpes keratitis. However, this drug has never been successful in the topical treatment of blisters on the face and lips. It was demonstrated that the initial success of the cytarbine (cytarbine) [anti-tumor agent] and heterocyclic dye / incandescent therapy was illusory.

The most common methods of relieving the effects of herpesviruses include topical application of various drugs. Although effective local treatment was expected to prevent viral replication and promote healing in the affected area, it was ineffective against latent virus. As such, systemic treatments are unknown.

Various chemical agents are described in the patent literature for skin rashes, which also include certain components of the therapeutic compositions of the present invention. As early as 1872 Bergengren (US124460) described a skin potion composed of boric acid, potassium chloride and citric acid added to certain flowers and spices.

Alcohols of salicylic acid and boric acid for the treatment of topical skin diseases caused by plant parasites (eg beetles, “mimushi”)
Nicholas, using glycerin solution
US2095511, October 12, 1937). Salicylic acid is used as a fungal inhibitor at a concentration of 3 to 10% by weight, and boric acid is added for itching and antiseptic properties. Plane (Prenn, US2175
780, October 10, 1939) describe a powder formulation containing salicylic acid, methanol and camphor in a powder carrier consisting of boric acid and starch for topical treatment against fungi and dermatitis.

Combinations of boric acid and tannic acid in skin treatment compositions are also disclosed in the literature. Jekel, US397
0032, January 31, 1961) disclose the combination of certain tannin / boric acid reaction products in a special solvent for use in the treatment of filamentous fungi. Shelton
ton, US2276241, Marc H10, 1942) describes an aqueous pharmaceutical composition for the treatment of skin infections consisting of a catechol tannin extract for a soothing effect, a phenolic antiseptic compound and boric acid for pH adjustment.

It has now been discovered by the present invention that a highly specific combination of constituents is highly effective in the topical treatment of herpesvirus diseases.

According to the invention about 2 to 12% by weight of tannic acid, about 2-1
A composition for the topical treatment of herpesvirus affected areas containing 2% by weight boric acid and about 1-6% by weight salicylic acid and the balance a suitable liquid carrier such as ethanol and a method of using the composition are provided. Provided. Preference is given to using approximately 2 to 7% by weight tannic acid, approximately 2 to 7% by weight boric acid and approximately 1 to 5% by weight salicylic acid in the above composition range. Higher concentrations may be more effective but may cause irritation or itch to sensitive mucous membranes; above 8% by weight salicylic acid causes irritation and discomfort. Therefore, for infections of the tongue, cheeks or genital mucosa, the lowest concentration in the preferred range is used.

The composition of the present invention contains about 7-14% by volume (defined value) of solid particles in a clear solution, which particles are shaken into a slurry prior to application.

Treatment is achieved by applying a small amount of the above suspension directly to the affected area using a cotton swab, soft brush or sponge. It is effective to use a sufficient amount of suspension to cover the affected area. Application is twice daily for about 3 days.
The use of a more concentrated solution subsides the erythema, pain and itching within 4-12 hours after the first application and heals within 48-72 hours. In almost all cases, pain is virtually salvaged within less than one hour of initial treatment. The affected area clears within 4-5 days with little or no scalp. If the patient begins treatment on the first day they notice a rash, the infection generally does not reach the blistering stage and neither secondary infections nor peripheral spread occur.

Successful relief of herpesvirus disease on the external skin surface, tongue, buccal mucosa and genitals is markedly accelerated by the therapeutic treatment according to the invention, although it is not recommended for herpes infections to the eye; this suspension This is because the acidity of causes inflammation of eye tissues.

For unknown reasons, the therapeutic treatment according to the invention appears to have a blunting effect on the virus, prolonging the time between relapses substantially and in some cases apparently eliminating the virus altogether. Resulting in. The present inventor has also found that the above composition is effective for leukopla of the oral cavity and vulva.
It was found to be effective in treating acne and contact dermatitis.

The particular combination of ingredients according to the invention appears to have a synergistic effect in the treatment of affected areas of herpesvirus disease, vitiligo disease, acne and contact dermatitis as compared to solutions of each ingredient alone (multiple) or other combinations. . The relative effects are shown in Table 1, which illustrates the healing effect of treated patients on various types of herpesvirus-induced rashes using ethanolic solutions of each composition.

The solution (s) having the concentrations of the components in the suspension according to the present invention used in the above-mentioned experiment (Table 1) approximately doubled, were most effective in substantially promoting healing to the affected part on the non-mucosal membrane. Was found. The concentrations of the above-mentioned components are recommended as recommended values, but there is no contraindication to these.

The solvent / carrier may be any solvent / carrier that does not cause an appreciable reaction with the drug component to reduce the efficacy and does not irritate the skin. Alcohol, water or mixtures thereof are all suitable carriers. The alcohol is preferably ethanol, isopropyl alcohol or methanol; the reason alcohols are preferred is that they do not vaporize rapidly and have a negative effect on the skin.
Typical solvent / carrier is 70% IPA (aqueous), 95%
Ethanol and 50% methanol.

The mixtures according to the invention are easily prepared by weighing the normal amounts of the components, adding them individually or together to the liquid phase and shaking the resulting mixture to accelerate the dissolution of the components. Additional ingredients (eg, emollients) can be used as long as they do not compromise the effectiveness of the solution of the present invention.

The following examples illustrate the invention: As a result of observing a number of cases of infection with herpes simplex at different parts of the body, the therapeutic treatment according to the invention predictively pains in less than 12 hours (usually less than 1 hour). Hold down, then usually 2
Clean the affected area within 4-5 days compared to ~ 3 weeks. Furthermore, it has been observed that viral transmission to others by lip or sexual contact ceases after treatment of the affected area within about 24-48 hours. In the absence of treatment according to the invention, patients with genital herpes need to have sexual intercourse for three weeks. Furthermore, it has been observed that patients who develop continuous recurrences of herpes simplex virus appear to become immunized in subsequent relapses with several treatments according to the invention.
The extinction of the peripheral inoculated virus is theoretically possible to extinguish the central latent virus after multiple local treatments.

It has been found that treating the affected area prior to rupture of the bleb generally avoids secondary infections that often occur after rupture. Secondary infections prolong the pain period for as long as 5 to 7 days and usually require treatment with antibiotics before the infection resolves.

Although the present invention has been described in detail with respect to a particular therapeutic solution, it is understood that certain modifications may be made within the spirit and scope of the present invention, i.e., in relation to the three acid components in the therapeutic solution. It should be understood by business engineers. The addition of other antiviral agents, emollients and the like may be contemplated. Further solvent / carrier changes may also be contemplated. Therefore, the present invention should be limited only by the claims.

Claims (1)

[Claims] 1. Boric acid, tannic acid and salicylic acid are added in an amount of 2 to 5.
A composition for treating diseases caused by herpes virus, which is contained in a weight ratio of 12: 2 to 12: 1 to 6.